Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
TEDDY - The Environmental Determinants of Diabetes in the Young
This study is currently recruiting participants.
Verified by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), November 2008
Sponsors and Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of Allergy and Infectious Diseases (NIAID)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute of Environmental Health Sciences (NIEHS)
Juvenile Diabetes Research Foundation
Centers for Disease Control and Prevention
Information provided by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov Identifier: NCT00279318
  Purpose

The long-term goal of the TEDDY study is the identification of infectious agents, dietary factors, or other environmental agents, including psychosocial factors which trigger T1DM in genetically susceptible individuals or which protect against the disease. Identification of such factors will lead to a better understanding of disease pathogenesis and result in new strategies to prevent, delay or reverse T1DM.


Condition
Type 1 Diabetes Mellitus

MedlinePlus related topics: Diabetes Diabetes Type 1
U.S. FDA Resources
Study Type: Observational
Study Design: Prospective
Official Title: Consortium for Identification of Environmental Triggers of Type 1 Diabetes

Further study details as provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):

Biospecimen Retention:   Samples With DNA

Biospecimen Description:

Serum, plasma, stool, saliva, nail clippings, water


Estimated Enrollment: 7801
Study Start Date: September 2004
Estimated Study Completion Date: September 2023
Detailed Description:

Epidemiologic patterns suggest that viruses, nutrition, toxic agents or socioeconomic psychosocial factors may contribute to the etiology alone or in combination. Elucidation is confounded by the long interval between exposure and onset of clinical disease, as well as the interaction of multiple genes and/or insults, which appear to interact in a complex manner. Numerous studies have investigated environmental influences but have yielded conflicting results. This may be in part due to the failure to account for genetic susceptibility, begin observation at early ages or in utero, and/or monitor subjects long term and frequently.

Hypotheses:

  1. Initiation of persistent beta-cell autoimmunity and progression from beta-cell autoimmunity to diabetes is increased with:

    1. Exposure to a trigger factor during pregnancy, such as infections, preeclampsia, blood incompatibility, or birth weight.
    2. Differences in the timing of the introduction and/or the type of dietary constituents that include exposure to cereals or gluten, exposure to cow's milk during infancy and/or childhood, and short duration of breast- feeding;
    3. Lower intake of serum 25 hydroxyvitamin D in early infancy, vitamin E, anti-oxidants (e.g., carotenoids, ascorbic acid, selenium, or omega-3 fatty acids);
    4. Higher frequency of specific (e.g., enterovirus, rotavirus, or bacterial) infections, or non-specific childhood infections including those that exhibit molecular mimicry;
    5. Increased exposure to routine childhood immunizations and their timing;
    6. Environmental factors that may be contained in drinking water (e.g., low concentrations of zinc or high concentrations of nitrates, or lower pH levels);
    7. Exposure to household pets, and various allergies;
    8. Excessive weight gain;
    9. Increased psychological stress.
  2. The risk of persistent beta-cell autoimmunity is lower in children from the general population than in offspring or siblings of T1DM patients when stratifying for the HLA DR-DQ genotype and exposure to environmental triggers.
  3. The interaction of HLA DR-DQ genotype with exposure to dietary or infectious factors leads to increased incidence of beta-cell autoimmunity and T1DM.
  4. We expect that in some families study participation will be associated with affective (anxiety, depression) and behavioral responses (e.g. actions to prevent possible T1DM).
  Eligibility

Ages Eligible for Study:   up to 4 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Childen up to 4 months of age with specified HLA are enrolled and followed longitudnally

Criteria

Inclusion Criteria:

  • Newborns with high risk HLA in the general population or having a first- degree relative affected with T1DM
  • Newborns are less than 4 months of age

Exclusion Criteria:

  • Have an illness or birth defect that precludes long-term follow-up or involves use of treatment that may alter the natural history of diabetes (e.g. steroids or insulin)
  • Refuses to have blood and stool samples stored at the NIDDK Repository
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00279318

Locations
United States, Colorado
University of Colorado Health Sciences Center Recruiting
Denver, Colorado, United States, 80262
Contact: Judith Baxter, MA     303-315-6857     judy.baxter@uchsc.edu    
Principal Investigator: Marian Rewers, MD, PhD            
United States, Florida
Medical College of Georgia Recruiting
Gainesville, Florida, United States, 32608
Contact: Angie Choate     352-334-0843     choatal@peds.ufl.edu    
Principal Investigator: Jin-Xiong She, PhD            
United States, Georgia
Medical College of Georgia Recruiting
Augusta, Georgia, United States, 30912
Contact: Diane I Hopkins, MS, CCRC     706-721-4161     dhopkins@mcg.edu    
Principal Investigator: Jin-Xiong She, PhD            
Medical College of Georgia Recruiting
Atlanta, Georgia, United States, 30342
Contact: Leigh Steed, RN,CDE,CCRC     404-252-0844     lsteed@mail.mcg.edu    
Contact: Kate Silvis, MS, RD, LD     404-252-0844     ksilvis@mail.mcg.edu    
Principal Investigator: Jin-Xiong She, PhD            
United States, New York
Naomi Berrie Diabetes Center, Columbia University Medical Center (this site is only screening babies whose mother, father or full sibling have type 1 diabetes) Recruiting
New York, New York, United States, 10032
Contact: Diana Arnold     212-851-5466     dea2101@columbia.edu    
Sub-Investigator: Robin Goland, MD            
United States, Pennsylvania
Children's Hospital of Pittsburgh of UPMC (this site is only screening babies whose mother, father or full sibiling have type 1 diabetes) Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Peggy Franciscus     412-692-5250     margaret.franciscus@chp.edu    
Sub-Investigator: Dorothy Becker, MD            
United States, Washington
Pacific Northwest Research Institute Recruiting
Seattle, Washington, United States, 98122
Contact: William Hagopian, MD, PhD     206-726-1200     wah@u.washington.edu    
Principal Investigator: William Hagopian, MD, PhD            
Finland
Turku University Central Hospital Recruiting
Turku, Finland, 20520
Contact: Olli Simell, MD, PhD     358-2-313 2466     olli.simell@utu.fi    
Contact: Tuula Simell, MPH, PhD     358-2-313 3427     tuula.simell@utu.fi    
Principal Investigator: Olli Simell, MD, PhD            
Germany
Diabetes Research Institute Recruiting
Munich, Germany, 80804
Contact: Anette G. Ziegler, MD     0049 / 89 / 30 79 31-21     anziegler@lrz.uni-muenchen.de    
Contact: Christiane Winkler     0049 / 89/ 30 79 31-14     christiane.winkler@lrz.uni-muenchen.de    
Principal Investigator: Anette G. Ziegler, MD            
Sweden
University of Lund Recruiting
Malmo, Sweden, 20502
Contact: Barbro Lernmark, PhD     46 40 332390     barbro.lernmark@med.lu.se    
Contact: Ake Lernmark, MD, PhD     46 40 336963     ake.lernmark@med.lu.se    
Principal Investigator: Ake Lernmark, MD, PhD            
Sponsors and Collaborators
Juvenile Diabetes Research Foundation
Investigators
Principal Investigator: Jeffrey P. Krischer, PhD University of South Florida
Principal Investigator: Marian J. Rewers, MD, PhD University of Colorado Health Science Center
Principal Investigator: William A. Hagopian, MD, PhD Pacific Northwest Research Institute
Principal Investigator: Ake Lernmark, MD, PhD University of Washington & University of Lund
Principal Investigator: Olli G. Simell, MD, PhD University of Turku
Principal Investigator: Jin-Xiong She, PhD Medical College of Georgia
Principal Investigator: Anette G. Ziegler, MD University of Miami
Principal Investigator: Beena Akolkar, PhD National Institutes of Diabetes and Digestive Kidney Diseases
  More Information

TEDDY Study Public site  This link exits the ClinicalTrials.gov site

Responsible Party: University of South Florida ( Dr. Jeffrey Krischer )
Study ID Numbers: DK63790, 5U01DK063790-04
Study First Received: January 17, 2006
Last Updated: November 5, 2008
ClinicalTrials.gov Identifier: NCT00279318  
Health Authority: United States: Federal Government;   United States: Institutional Review Board

Keywords provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):
Environment
Exposures
Diet
Toxins
Psychosocial
Infectious Agents
Bacterial
Viral
Immunizations
Autoantibody

Study placed in the following topic categories:
Autoimmune Diseases
Metabolic Diseases
Autoantibodies
Diabetes Mellitus, Type 1
Diabetes Mellitus
Endocrine System Diseases
Endocrinopathy
Metabolic disorder
Glucose Metabolism Disorders

Additional relevant MeSH terms:
Immune System Diseases

ClinicalTrials.gov processed this record on January 16, 2009